10-K: Heron Therapeutics 2025: Acute Care Drives Revenue Growth

Heron Therapeutics reports increased net product sales driven by strong acute care performance, despite a net loss and ongoing patent litigation for its oncology products.

Summary

• Net product sales increased 7.4% to $154.9 million in 2025 from $144.3 million in 2024.
• Acute care net product sales grew 65.1% in 2025, primarily due to increased market share and new customers for ZYNRELEF and APONVIE.
• Oncology net product sales decreased 7.8% in 2025, mainly due to higher gross-to-net adjustments for market share maintenance and a 6.7% decrease in SUSTOL units sold, partially offset by a 21.8% increase in CINVANTI units sold.
• Net loss for 2025 was $20.2 million ($0.12 per share), compared to $13.6 million ($0.09 per share) in 2024.
• Cash, cash equivalents, and short-term investments totaled $46.6 million as of December 31, 2025.
• Management believes existing cash will be sufficient to meet anticipated cash requirements for at least one year from the filing date (February 26, 2026).
• Ongoing patent litigation for CINVANTI and APONVIE against generic manufacturers (Fresenius Kabi, Mylan, Azurity, Qilu, Baxter) continues, with some settlements reached for generic launch dates in June 2032.
• Commercialization of SUSTOL is winding down over the next 12 months, with potential reintroduction as early as late 2027 after product updates.
• Entered a co-promotion agreement with Crosslink Network in January 2024 to expand ZYNRELEF promotion for orthopedic indications.
• Total operating expenses decreased slightly to $116.1 million in 2025 from $117.2 million in 2024.
• A loss on debt extinguishment of $11.3 million was recorded in 2025.
• Total purchase obligations of $19.0 million are due within one year as of December 31, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed report. Strong acute care product growth and positive patent litigation outcomes are encouraging, but the increased net loss, decline in oncology sales, and the winding down of SUSTOL indicate ongoing challenges and strategic adjustments. The capital raise and debt restructuring provide liquidity but also reflect continued funding needs.

Positives

• Total net product sales increased by 7.4% to $154.9 million in 2025.
• Acute care net product sales surged by 65.1% in 2025, driven by ZYNRELEF and APONVIE.
• ZYNRELEF received FDA approval for a Vial Access Needle (VAN) in September 2024.
• ZYNRELEF is included in the NOPAIN Act, ensuring separate Medicare reimbursement in Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through December 31, 2027.
• CMS approved a new permanent Healthcare Common Procedure Coding System (J-code) for ZYNRELEF effective October 1, 2025, aligning with non-opioid pain relief policy goals.
• APONVIE was included in the Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting in 2025.
• CINVANTI units sold increased by 21.8% in 2025.
• Research and development expense decreased by 25.5% ($4.3 million) in 2025, partly due to personnel cost reductions.
• A court ruled in the company's favor in CINVANTI patent litigation against Fresenius Kabi in December 2024, finding patents valid and infringed, delaying generic entry until September 18, 2035.
• Settlement agreements were reached with Mylan and Qilu for generic CINVANTI and APONVIE, granting licenses to market generic versions starting June 1, 2032.
• Management believes existing cash, cash equivalents, and short-term investments of $46.6 million are sufficient for at least one year from the filing date (February 26, 2026).
• A private placement equity offering in August 2025 raised aggregate gross proceeds of $27.7 million.
• Stockholders approved the issuance of common stock for the conversion of 2031 Convertible Notes and Series A convertible preferred stock in October 2025.

Negatives

• Net loss increased to $20.2 million in 2025 from $13.6 million in 2024.
• Oncology net product sales decreased by 7.8% in 2025.
• SUSTOL units sold decreased by 6.7% in 2025, and its commercialization is being wound down.
• Cost of product sales increased by 7.0% ($2.7 million) in 2025, partly due to a $2.1 million increase in inventory reserves and write-offs.
• Interest expense increased by $3.6 million in 2025.
• A loss on debt extinguishment of $11.3 million was recorded in 2025.
• Cash used in operating activities increased to $27.6 million in 2025 from $22.5 million in 2024.
• The company has a history of losses and expects to generate losses in the near future, with an accumulated deficit of $1.94 billion as of December 31, 2025.
• Total indebtedness stands at $147.1 million as of December 31, 2025.
• The patent on the Biochronomer technologies expires in April 2026.
• Development of HTX-034 is paused to evaluate the program and market potential.

Risks

• Substantial dependence on the commercial success of its current products (ZYNRELEF, APONVIE, CINVANTI, and SUSTOL).
• Inability to maintain satisfactory pricing or obtain adequate reimbursement from government and third-party payors.
• Failure to comply with U.S. governmental pricing and contracting programs could lead to additional reimbursement requirements, penalties, and fines.
• Reliance on a small number of third-party manufacturers and single suppliers for critical materials, which could lead to delays, increased costs, or supply disruptions.
• Intense competition from other companies, including lower-cost generic products, in the postoperative pain management and CINV/PONV prevention markets.
• Product platforms or product development efforts may not produce safe, efficacious, or commercially viable products.
• Inability to recruit and retain skilled employees.
• Risks associated with international expansion, acquisitions of other businesses, products, or product licenses.
• Potential inability to enter into or successfully manage collaborative agreements.
• Disruptions from natural or man-made disasters, epidemics, pandemics, cyberattacks, acts of war or terrorism, armed conflict, or resource shortages.
• History of losses and expectation of future losses; may never achieve or maintain profitability.
• Need for additional capital in the future, with potential for stockholder dilution or restrictive debt covenants.
• Exposure to significant product liability claims.
• Risk that service providers may be characterized as employees, leading to employment and tax withholding liabilities.
• Investment of cash is subject to general credit, liquidity, market, and interest rate risks.
• Adverse developments affecting the financial services industry could adversely affect business operations and financial condition.
• Failure to comply with continuing federal, state, and foreign regulations could result in loss of marketing approvals.
• Commercial use of products may cause unintended side effects, adverse reactions, or incidents of misuse.
• Significant regulation and oversight under anti-kickback laws, false claims statutes, and anti-corruption laws, potentially leading to substantial fines or penalties.
• Risk of incurring significant liability if determined to be promoting 'off-label' use of drugs or promoting in a non-truthful and misleading way.
• Healthcare reform measures could increase expenses and adversely affect the commercial success of products.
• Use of hazardous materials could subject the company to liabilities, fines, and sanctions.
• Employee misconduct or other improper activities.
• Stringent and evolving laws, regulations, rules, contractual obligations, policies, and other obligations related to data privacy and security.
• Security breaches and other disruptions could compromise information and expose the company to liability.
• Changes in government policies, laws, and regulations, including tariffs and trade policies, may negatively impact the business.
• Inability to adequately protect or enforce intellectual property rights, or claims of infringement by others.
• Volatility and unpredictability of the common stock price.
• Corporate governance provisions and Delaware law that could discourage acquisitions and prevent attempts by stockholders to replace management.
• Future utilization of net operating loss carryforwards or research and development credit carryforwards may be impaired due to changes in ownership.
• Actions of activist stockholders could impact business strategies, cause substantial costs, and divert management attention.
• Potential for material weakness in internal control over financial reporting.
• No anticipated cash dividends on common stock in the foreseeable future.

Future Outlook

Management projects that existing cash, cash equivalents, and short-term investments will be sufficient to meet anticipated cash requirements for at least one year from the filing date. The company plans to wind down commercialization of SUSTOL over the next 12 months, with a potential reintroduction as early as late 2027, subject to development progress, manufacturing readiness, and regulatory feedback. Development of HTX-034 is currently paused for evaluation. The company anticipates continued focus on healthcare reform measures, including potential changes to Medicare payment policies, which could impact drug pricing and reimbursement. A new mandatory Medicare OPPS Drug Acquisition Cost Survey will be conducted from January 1, 2026, through March 31, 2026, to inform future payment policy changes.

Management Comments

• "Management believes that the Company's cash, cash equivalents and short-term investments will be sufficient to meet the Company's anticipated cash requirements for a period of at least one year from the date this Annual Report on Form 10-K is filed with the U.S. Securities and Exchange Commission."
• "We intend to wind down commercialization of SUSTOL over the next 12 months while we evaluate potential product updates. Subject to development progress, manufacturing readiness, and regulatory feedback, we may consider reintroducing SUSTOL as early as late 2027."

Industry Context

StockSavvy.ai notes that Heron Therapeutics operates in highly competitive biotechnology and pharmaceutical industries, facing larger, more resourced competitors. The company's focus on acute care and oncology, particularly with non-opioid pain management (ZYNRELEF) and PONV/CINV prevention (APONVIE, CINVANTI), aligns with broader industry trends towards reducing opioid dependence and improving patient care in surgical and chemotherapy settings. The inclusion of ZYNRELEF in the NOPAIN Act and the approval of a J-code are significant regulatory tailwinds, reflecting a favorable policy environment for non-opioid alternatives. However, the decline in oncology sales and the winding down of SUSTOL highlight the intense competition and rapid evolution within specific therapeutic areas, requiring continuous innovation and strategic adaptation. The ongoing patent litigations are typical for the pharmaceutical industry, where intellectual property protection is crucial for market exclusivity and revenue generation.

Comparison to Industry Standards

• The 65.1% growth in acute care net product sales for ZYNRELEF and APONVIE is a strong performance, potentially outpacing many new product launches in the pharmaceutical industry, especially given the competitive landscape.
• The inclusion of ZYNRELEF in the NOPAIN Act and the assignment of a permanent J-code by CMS are critical for market access and reimbursement, positioning it favorably against competitors like Pacira BioSciences' EXPAREL, which also targets extended-release local analgesia. This regulatory support is a key differentiator.
• The decline in oncology sales, particularly for SUSTOL, suggests challenges in a segment with established competitors like Merck's EMEND and Helsinn's AKYNZEO. The decision to wind down SUSTOL's commercialization indicates a strategic shift, potentially due to market saturation or superior alternatives.
• The successful defense of CINVANTI patents against Fresenius Kabi, delaying generic entry until 2035, is a significant win, providing a longer period of market exclusivity compared to typical generic challenges which often result in earlier settlements. Settlements with Mylan and Qilu for 2032 generic entry for CINVANTI and APONVIE are also within the expected range for such patent disputes, providing clarity on future revenue streams.
• The net loss of $20.2 million, while an improvement from previous years, indicates that the company is still in a growth phase requiring significant investment, which is common for commercial-stage biotechnology companies with a portfolio of recently launched products.

Corporate Governance

Legal Proceedings

• **Fresenius Kabi (CINVANTI)**: The company filed a patent infringement complaint on July 27, 2022, in response to Fresenius Kabi's ANDA. A court ruled in the company's favor on December 3, 2024, finding patents valid and infringed, delaying generic entry until September 18, 2035. Fresenius Kabi filed an appeal on January 8, 2025, with briefing completed on September 24, 2025.
• **Mylan (CINVANTI & APONVIE)**: The company settled patent litigation with Mylan on May 6, 2025, granting Mylan a license to market generic CINVANTI and APONVIE in the United States beginning June 1, 2032.
• **Slayback Pharma LLC (Azurity) (CINVANTI)**: The company filed a patent infringement complaint on January 24, 2024, in response to Slayback's NDA. A two-day bench trial commenced on November 17, 2025, with post-trial briefing completed on February 6, 2026. FDA approval for Slayback's ANDA may not occur before June 12, 2026, or resolution of the litigation.
• **Azurity Pharma India LLP and Slayback (CINVANTI PGRs)**: The Patent Trial and Appeal Board discretionarily denied institution of Azurity's Post-Grant Reviews of CINVANTI patents on August 14, 2025.
• **Qilu Pharmaceutical (APONVIE & CINVANTI)**: The company filed patent infringement complaints in March and July 2025. The litigations were consolidated on July 15, 2025, and subsequently settled on November 6, 2025, dismissing the pending litigation.
• **Baxter Healthcare Corporation (CINVANTI)**: The company filed a patent infringement complaint on December 23, 2025, in response to Baxter's ANDA. FDA approval for Baxter's ANDA for generic CINVANTI may not occur before May 19, 2028, or resolution of the litigation.

Related Party Transactions

• The company entered into a Note Purchase Agreement and a Cooperation Agreement on August 8, 2025, with a fund affiliated with Rubric Capital Management LP, a significant stockholder.

Stakeholder Impact

• **Shareholders**: Experience dilution from recent equity financings, face stock price volatility, and are subject to the influence of activist stockholders. Capital appreciation is the primary source of gain as no cash dividends are anticipated.
• **Employees**: Benefit from a robust total rewards package, including base salary, cash bonuses, long-term equity compensation, and comprehensive benefits. The company supports employee development and workplace safety.
• **Customers (Healthcare Providers/Hospitals)**: Benefit from continued access to ZYNRELEF, APONVIE, and CINVANTI. ZYNRELEF's inclusion in the NOPAIN Act and new J-code improve reimbursement and access for non-opioid pain management.
• **Suppliers/Contract Manufacturers**: The company's reliance on a limited number of third-party manufacturers and single suppliers creates potential risks for supply chain disruptions and increased costs.
• **Creditors**: The company has significant indebtedness under its Working Capital Facility and Convertible Notes, which include restrictive covenants. The ability to raise additional capital is crucial to meet obligations.

Next Steps

• Wind down commercialization of SUSTOL over the next 12 months.
• Evaluate potential product updates for SUSTOL, with possible reintroduction as early as late 2027.
• Continue to support customers and manage inventory responsibly during the SUSTOL wind-down.
• Quantify one-time transition costs for SUSTOL wind-down as plans are finalized.
• Await date for oral argument in Fresenius Kabi's appeal of the CINVANTI patent litigation.
• Await date for oral argument in Azurity's CINVANTI patent litigation post-trial briefing.
• Vigorously enforce intellectual property rights relating to CINVANTI against Baxter.
• CMS to conduct a new mandatory Medicare OPPS Drug Acquisition Cost Survey from January 1, 2026, through March 31, 2026, to inform potential changes to payment policy beginning with calendar year 2027.
• New office lease in Cary, North Carolina, expected to commence no later than May 25, 2026.
• Continue to monitor and adapt to global economic and political developments, including inflation, interest rate fluctuations, and geopolitical conflicts.

Key Dates

Recommendation

Heron Therapeutics demonstrates promising growth in its acute care portfolio, particularly with ZYNRELEF benefiting from favorable reimbursement policies and successful patent defense. However, the continued net losses, decline in oncology sales, and the strategic decision to wind down SUSTOL commercialization introduce uncertainty. While recent capital raises and debt restructuring provide near-term liquidity, the company's long-term profitability remains unproven. Investors should hold, monitoring the sustained growth of acute care products, the successful re-evaluation and potential reintroduction of SUSTOL, and the company's path to profitability.

Keywords

Biotechnology, Pharmaceuticals, Acute Care, Oncology, ZYNRELEF, APONVIE, CINVANTI, SUSTOL, Postoperative Pain, Nausea and Vomiting, Chemotherapy-Induced Nausea and Vomiting, Biochronomer Technology, Patent Litigation, Drug Development, Commercialization, Healthcare Regulation, Financial Performance